• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    12/23/22 12:31:12 PM ET
    $ACON
    $AMTI
    $CABA
    $CCM
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACON alert in real time by email

    Gainers

    • Immuron (NASDAQ:IMRN) shares increased by 37.9% to $2.22 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 17.1 million shares, making up 288523.4% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $12.6 million.
    • Scopus BioPharma (NASDAQ:SCPS) shares increased by 25.0% to $0.1. As of 12:30 EST, this security is trading at a volume of 85.9K shares, making up 8.9% of its average full-day volume over the last 100 days. The company's market cap stands at $2.1 million.
    • DBV Technologies (NASDAQ:DBVT) shares moved upwards by 21.18% to $1.43. As of 12:30 EST, DBV Technologies's stock is trading at a volume of 5.8 million, which is 8279.5% of its average full-day volume over the last 100 days. The company's market cap stands at $268.7 million.
    • ORIC Pharmaceuticals (NASDAQ:ORIC) stock increased by 19.62% to $5.73. Trading volume for ORIC Pharmaceuticals's stock is 7.4 million as of 12:30 EST. This is 1310.4% of its average full-day volume over the last 100 days. The company's market cap stands at $226.7 million.
    • Concord Medical Services (NYSE:CCM) stock moved upwards by 19.13% to $1.62. The market value of their outstanding shares is at $70.3 million.
    • Aclarion (NASDAQ:ACON) stock moved upwards by 16.83% to $0.48. The market value of their outstanding shares is at $3.7 million.

    Losers

    • Applied Molecular (NASDAQ:AMTI) stock decreased by 53.4% to $0.48 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 2.9 million shares, making up 1803.4% of its average full-day volume over the last 100 days. The company's market cap stands at $18.6 million.
    • NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares decreased by 38.76% to $0.79. As of 12:30 EST, this security is trading at a volume of 6.0 million shares, making up 192.8% of its average full-day volume over the last 100 days. The company's market cap stands at $5.1 million.
    • Miromatrix Medical (NASDAQ:MIRO) shares declined by 23.22% to $2.15. The current volume of 82.7K shares is 367.6% of Miromatrix Medical's average full-day volume over the last 100 days (last updated at 12:30 EST). The company's market cap stands at $44.9 million.
    • Otonomy (NASDAQ:OTIC) stock decreased by 21.05% to $0.07. The current volume of 3.5 million shares is 25.8% of Otonomy's average full-day volume over the last 100 days (last updated at 12:30 EST). The market value of their outstanding shares is at $3.9 million.
    • Exicure (NASDAQ:XCUR) shares declined by 19.53% to $1.18. Trading volume for this security as of 12:30 EST is 1.0 million, which is 520.7% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $5.8 million.
    • Cabaletta Bio (NASDAQ:CABA) shares decreased by 16.3% to $7.79. Trading volume for Cabaletta Bio's stock is 770.8K as of 12:30 EST. This is 58.3% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $226.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ACON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACON
    $AMTI
    $CABA
    $CCM

    CompanyDatePrice TargetRatingAnalyst
    Oric Pharmaceuticals Inc.
    $ORIC
    1/7/2026$22.00Overweight
    Piper Sandler
    DBV Technologies S.A.
    $DBVT
    12/15/2025$42.00Overweight
    Cantor Fitzgerald
    DBV Technologies S.A.
    $DBVT
    12/3/2025$35.00Buy
    Guggenheim
    Oric Pharmaceuticals Inc.
    $ORIC
    11/20/2025$25.00Outperform
    Evercore ISI
    Oric Pharmaceuticals Inc.
    $ORIC
    11/18/2025Peer Perform
    Wolfe Research
    Cabaletta Bio Inc.
    $CABA
    10/10/2025$14.00Buy
    Jefferies
    Oric Pharmaceuticals Inc.
    $ORIC
    9/4/2025$18.00Buy
    Guggenheim
    Oric Pharmaceuticals Inc.
    $ORIC
    7/8/2025$15.00Buy
    Ladenburg Thalmann
    More analyst ratings

    $ACON
    $AMTI
    $CABA
    $CCM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Chang David J. bought $19,888 worth of shares (8,800 units at $2.26) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:58 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    President, Science & Tech. Binder Gwendolyn bought $24,763 worth of shares (11,312 units at $2.19), increasing direct ownership by 57% to 31,312 units (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:56:30 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Tomasello Shawn bought $50,322 worth of shares (22,725 units at $2.21) (SEC Form 4)

    4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

    1/21/26 6:55:49 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AMTI
    $CABA
    $CCM
    SEC Filings

    View All

    SEC Form 144 filed by Oric Pharmaceuticals Inc.

    144 - Oric Pharmaceuticals, Inc. (0001796280) (Subject)

    2/24/26 4:08:44 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Oric Pharmaceuticals Inc.

    8-K - Oric Pharmaceuticals, Inc. (0001796280) (Filer)

    2/23/26 5:06:19 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Oric Pharmaceuticals Inc.

    424B5 - Oric Pharmaceuticals, Inc. (0001796280) (Filer)

    2/23/26 5:02:58 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AMTI
    $CABA
    $CCM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on ORIC Pharmaceuticals with a new price target

    Piper Sandler initiated coverage of ORIC Pharmaceuticals with a rating of Overweight and set a new price target of $22.00

    1/7/26 9:13:12 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on DBV Technologies with a new price target

    Cantor Fitzgerald initiated coverage of DBV Technologies with a rating of Overweight and set a new price target of $42.00

    12/15/25 9:59:53 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Guggenheim initiated coverage on DBV Technologies with a new price target

    Guggenheim initiated coverage of DBV Technologies with a rating of Buy and set a new price target of $35.00

    12/3/25 8:16:35 AM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AMTI
    $CABA
    $CCM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Immuron Reports HY26 Results and Strategic Reset

    Highlights (unaudited): Consistent Revenue Growth: Immuron is no longer just a "concept" company. Global H1 FY26 sales grew to AUD$4.2 million, with the U.S. market showing strong momentum (+17% YoY).Cash (AUD $10.0 million) to fund operating activities. Includes AUD $7.3 million (net) raised at an average price of A$0.0803 (IMRN USD$2.0923).Validated Platform: The "Hyper-Immune" platform is versatile. Beyond traveler's diarrhea (Travelan®), the company is moving into high-value clinical targets like C. diff (IMM-529)Partnerships: Immuron has taken a strategic decision to pursue partnerships to fund progress of Travelan® (IMM-124E) and IMM-529 clinical programs. IMM-124E: Eligible for end o

    2/25/26 6:00:00 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cabaletta Bio to Participate in the TD Cowen 46th Annual Health Care Conference

    PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 11:10 a.m. ET in Boston, MA. A live webcast of the presentation will be available on the News and Events section of the Company's website at www.cabalettabio.com. Replays will be available on the website for 30 days. About Cabaletta BioCabaletta Bio (NASDAQ:CABA) is a late-stage

    2/24/26 8:00:00 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Updates

    Reported rinzimetostat (formerly ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose Raised $264 million from top-tier healthcare specialist funds; Cash and investments expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout for rinzimetostat Phase 3 study Expect to report multiple clinical da

    2/23/26 4:05:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AMTI
    $CABA
    $CCM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Piscitelli Dominic exercised 52,000 shares at a strike of $4.36 and sold $702,686 worth of shares (52,000 units at $13.51) (SEC Form 4)

    4 - Oric Pharmaceuticals, Inc. (0001796280) (Issuer)

    2/26/26 4:47:24 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Accounting Officer Miller Josh covered exercise/tax liability with 8 shares, decreasing direct ownership by 3% to 301 units (SEC Form 4)

    4 - EXICURE, INC. (0001698530) (Issuer)

    2/19/26 2:27:21 PM ET
    $XCUR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Mohideen Pharis sold $2,595 worth of Ordinary Shares (534 units at $4.86), decreasing direct ownership by 0.37% to 144,995 units (SEC Form 4)

    4 - DBV Technologies S.A. (0001613780) (Issuer)

    2/2/26 4:30:20 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AMTI
    $CABA
    $CCM
    Leadership Updates

    Live Leadership Updates

    View All

    ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones

    Announced rinzimetostat (ORIC-944) Phase 1b data that continue to demonstrate potential best-in-class efficacy and safety in mCRPC; selected provisional RP2Ds and initiated dose optimization in combination with AR inhibitors Presented potential best-in-class enozertinib Phase 1b data demonstrating highly competitive systemic and intracranial activity in NSCLC patients with EGFR exon 20 and EGFR PACC mutations; selected Phase 3 monotherapy dose Raised $244 million from top-tier healthcare specialist funds; Cash and investments of $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readout for rinzimetostat Phase 3 study Expect to report multiple cli

    1/12/26 8:30:00 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

    Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companiesStrong track record of launching breakthrough technologies across spine, neurosurgery and pain managementStrengthens Aclarion's commercial execution as the Company expands adoption and payer engagement across the Eastern U.S. BROOMFIELD, Colo., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (NASDAQ:ACON, ACONW)), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced the

    12/2/25 8:00:00 AM ET
    $ACON
    Medical Specialities
    Health Care

    ORIC® Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Clinical and Operational Updates

    Announced completion of dose exploration portion of ORIC-944 Phase 1b clinical trial and presented data that continues to demonstrate potential best-in-class efficacy and safety Bolstered leadership team with the appointment of Kevin Brodbeck, PhD, as Chief Technical Officer to further support ORIC's transition to potential late-stage development Cash and investments of approximately $413 million expected to provide runway into 2H 2028 and beyond anticipated primary endpoint readouts from first Phase 3 trials for ORIC-944 and enozertinib (ORIC-114) Expects to report four clinical data readouts across ORIC-944 and enozertinib (ORIC-114) programs through mid-2026, ahead of potential initiat

    11/13/25 4:10:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACON
    $AMTI
    $CABA
    $CCM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/6/24 4:05:57 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/5/24 4:50:19 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

    SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

    12/5/24 3:36:55 PM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ACON
    $AMTI
    $CABA
    $CCM
    Financials

    Live finance-specific insights

    View All

    DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years

    Châtillon, France, December 16, 2025 DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years VITESSE met its primary endpoint: the lower bound of the 95% confidence interval (CI) of the difference between treatment arms was 24.5%, exceeding the prespecified threshold of 15% 46.6% of children treated with the VIASKIN® Peanut patch met response criteria at 12 months, compared to 14.8% of children in the placebo arm Safety results were consistent with the safety profile observed in the VIASKIN Peanut clinical program to dateBLA submission in 4-7-year-olds on track for the first half of 2026Achievement

    12/16/25 4:05:00 PM ET
    $DBVT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

    Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable on-target toxicity, resulting in low discontinuation rate Enrollment and follow-up continue in 1L patients at selected dose of 80 mg once daily, with next update expected mid-2026 ahead of initiation of potential Phase 3 trial Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- OR

    12/5/25 8:00:00 PM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ORIC® Pharmaceuticals Presents Enozertinib Data in NSCLC Patients with HER2 Exon 20 Mutations at the ESMO Asia Congress 2025

    Systemic activity of 35% ORR in 2L+ patients, including in patients with active brain metastases Manageable safety profile with low discontinuation rate Enrollment completed; no further development planned in this patient population Company to host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced data from a Phase 1b trial of enozertinib (ORIC-114) at the ESMO Asia Congress 2025. Data in previously treated NSCLC pati

    12/5/25 1:00:00 AM ET
    $ORIC
    Biotechnology: Pharmaceutical Preparations
    Health Care